Immunome (IMNM) Non-Current Assets (2019 - 2026)

Immunome's Non-Current Assets history runs 8 years deep, the most recent figure standing at $25.5 million for Q1 2026.

• Quarterly Non-Current Assets rose 30.26% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.2 million (up 36.28% YoY) and the FY2025 annual result came in at $22.4 million, up 18.56% from the prior year.
• Non-Current Assets was $25.5 million for Q1 2026 at Immunome, up from $22.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $25.5 million in Q1 2026 and bottomed at $1.3 million in Q3 2022.
• A 5-year average of $10.0 million and a median of $6.4 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets dropped 4.46% — and 2024, when it soared 636.0%.
• Immunome's Non-Current Assets stood at $1.4 million in 2022, then jumped by 174.66% to $3.8 million in 2023, then surged by 392.62% to $18.9 million in 2024, then rose by 18.56% to $22.4 million in 2025, then advanced by 13.71% to $25.5 million in 2026.
• Business Quant data shows IMNM's Non-Current Assets at $25.5 million in Q1 2026, $22.4 million in Q4 2025, and $19.5 million in Q3 2025.